# Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

> **NCT07102394** · PHASE1 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 10 (estimated)

## Conditions studied

- NF1
- Neurofibromatosis
- Cutaneous Neurofibroma
- Neurofibroma
- Von Recklinghausen Disease
- Neurofibromas

## Interventions

- **DRUG:** Imlygic

## Key facts

- **NCT ID:** NCT07102394
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102394, "Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07102394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*